Cumulative incidence estimates of NRM and Kaplan–Meier survival estimates among nonmyeloablative compared with myeloablative patients with lymphoma or CLL and HCT-CI score of 1 or more. Nonmyeloablative patients had statistically significantly better outcomes compared with those of myeloablative patients. Differences between groups increased after adjustment for pretransplantation variables including age, previous HCT, previous regimens, previous CMV infection, type and stage of malignancy, donor type, and stem-cell source. — indicates observed outcomes for myeloablative patients; , observed outcomes for nonmyeloablative patients; and …, adjusted outcomes for nonmyeloablative patients.